ChemoCentryx, Inc. to Hold Third Quarter 2013 Financial Results Conference Call on Thursday, November 7, 2013

ChemoCentryx, Inc. logo

MOUNTAIN VIEW, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that the Company's third quarter 2013 financial results will be released after market close on Thursday, November 7, 2013. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on November 7, 2013, to discuss these results and to answer questions.

To participate by telephone, please dial 877-303-8028 (Domestic) or 760-536-5167 (International). The conference ID number is 95243286. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. Vercirnon (also known as Traficet-EN or CCX282), is a Phase III-ready specific CCR9 inhibitor, for the treatment of inflammatory bowel disease. CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis; CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis, as well as CCX872, a CCR2 inhibitor, and CCX507, an inhibitor of CCR9, both of which are in Phase I clinical testing. ChemoCentryx also has several programs in advanced preclinical development.

CCXI - G

Source: ChemoCentryx, Inc.

CONTACT: ChemoCentryx, Inc. Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer; or Markus J. Cappel, PhD Chief Business Officer investor@chemocentryx.com (650) 210-2900 Investors Caitlyn Murphy Burns McClellan cmurphy@burnsmc.com (212) 213-0006 Media Susan Kinkead Kinkead Communications susan@kinkead.com (415) 751-3611

Source:ChemoCentryx, Inc.